Short answer: injections and IV drips put NAD+ straight into the bloodstream, so they bypass digestion entirely and produce a large, immediate rise that clears within hours. Oral NMN works upstream instead — it supplies a precursor the cell converts on its own schedule, producing a smaller rise that is sustained by daily dosing. They are not the same intervention delivered two ways. They are two different strategies, and the choice is about what you want NAD+ levels to do over weeks, not over an afternoon.
What each delivery method actually does
IV and injection. NAD+ is infused as the finished molecule. Blood concentration rises sharply because nothing has to be absorbed, converted or transported first. The trade-off is that NAD+ is a large, charged molecule that does not cross cell membranes freely — so a high blood concentration is not automatically a high intracellular concentration, and intracellular is where the coenzyme does its work.
Oral NMN or NR. These are precursors. They are absorbed from the gut, distributed, and then converted to NAD+ inside cells through the salvage pathway. The rise is slower and smaller, but it happens inside the cell rather than in the plasma, and it is repeatable every day at low cost.
This is the distinction that most comparisons skip. A very large number in a blood test is not the same as the outcome you are buying.
What the human evidence supports
Oral precursors have the better-developed human record, which is worth stating plainly given that IV therapy is far more expensive.
Trammell and colleagues (2016) demonstrated that oral nicotinamide riboside raises NAD+ in human blood in a dose-dependent way — the first study to establish that an oral precursor moves the measurement in people, not only in animals. Martens and colleagues (2018) ran six weeks of chronic NR supplementation in healthy middle-aged and older adults and found it was well tolerated and effectively stimulated NAD+ metabolism.
On the NMN side, Irie and colleagues (2020) established single-dose oral safety in healthy men, and Yoshino and colleagues (2021) reported improved muscle insulin sensitivity after ten weeks of oral NMN in prediabetic women — a functional outcome, not just a biomarker.
Against that, published controlled trials of intravenous NAD+ in humans are sparse. What exists is largely small, uncontrolled, or focused on specific clinical contexts rather than on healthy adults seeking general support. The absence of trials is not evidence that IV does not work — but it does mean the confident claims made in clinic marketing are running well ahead of the published literature.
Cost, in the terms that matter
An NAD+ IV session is typically priced in the hundreds of dollars and takes one to several hours in a chair, because infusion is deliberately slow — pushed quickly, NAD+ commonly produces chest tightness, nausea and flushing, so the drip is throttled to tolerance. A course is usually sold as multiple sessions.
Daily oral NMN costs a small fraction of a single session per month. If NAD+ support is something you want continuously rather than episodically, the arithmetic is not close.
The honest case for each
IV makes sense if you specifically want a large acute exposure, you are working with a clinician, and you accept that you are paying for something with a thinner published evidence base than the oral route.
Oral makes sense if you want a daily, sustained, low-cost intervention with human trial data behind it, and you are willing to think in months rather than sessions. Most people asking this question want the second thing while assuming the first is simply a stronger version of it.
AE·ORA takes the oral route: NMN at 500 mg per capsule at 99.9% purity, and NAD+ Full Stack, which pairs NAD+ with quercetin and resveratrol. The two together are the Longevity Stack.
What to ask before booking a drip
Ask what dose is being infused, over what duration, and what evidence the clinic is relying on for the specific claim they are making. Ask whether they measure anything before and after. Ask who is supervising. A clinic that answers those four questions precisely is a different proposition from one that does not.
And if the goal is simply "support NAD+ over time", start with the cheaper, better-studied route and give it the ten to twelve weeks the trials used. See NMN Dosage and Side Effects and How NAD+ Precursors Actually Work.
Frequently Asked Questions
Quick answers to the questions readers most often ask.
Are NAD+ injections better than oral NMN?
Not straightforwardly. Injections and IV produce a much larger, faster rise in blood NAD+ because they bypass digestion, but NAD+ is a large charged molecule that does not cross cell membranes freely, so a high plasma level is not automatically a high intracellular level. Oral NMN supplies a precursor that cells convert internally, producing a smaller but sustained effect. Oral precursors also have the stronger published human trial record.
How long do NAD+ injections last?
The plasma rise from an infusion clears within hours, which is why clinics sell courses of repeated sessions rather than single visits. Oral precursors are designed around daily dosing instead, with human trials typically running eight to twelve weeks before measuring outcomes.
Why do NAD+ IV drips take so long?
Infused quickly, NAD+ commonly causes chest tightness, nausea and flushing. Clinics slow the drip to tolerance, which is why a session usually takes one to several hours rather than minutes.
Is there human evidence for NAD+ IV therapy?
Published controlled trials of intravenous NAD+ in healthy adults are sparse. Most available work is small, uncontrolled, or focused on specific clinical settings. Oral precursors have the better-developed record, including dose-dependent NAD+ elevation and a functional outcome trial in prediabetic women.
What does an NAD+ IV cost compared to oral NMN?
An IV session is typically priced in the hundreds of dollars and is usually sold as a multi-session course. Daily oral NMN costs a small fraction of one session per month, which is the main practical argument for the oral route if you want continuous rather than episodic support.
References
- Trammell SAJ et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016.
- Martens CR et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018.
- Irie J et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J. 2020.
- Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
